Therapeutic effect of orally administered microencapsulated oxaliplatin for colorectal cancer

Biomaterials

Volumn 33, Issue 18, 2012, Pages 4752-4761

  Urbanska, Aleksandra M ^a,c   Karagiannis, Emmanouil D ^a,c   Guajardo, Gonzalo ^a   Langer, Robert S ^a,b,c   Anderson, Daniel G ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Alginate; Colon cancer; Intestinal tumorigenesis; Oral delivery; Oxaliplatin

Indexed keywords

ADVERSE SIDE EFFECTS; CHEMOTHERAPEUTIC DRUGS; COLON CANCER; COLORECTAL CANCER; GASTROINTESTINAL TRACT; IN-VIVO; INTESTINAL TRACT; LOCAL DELIVERY; MICRO-PARTICLES; MOUSE MODELS; ORAL DELIVERY; ORTHOTOPIC; OXALIPLATIN; PH SENSITIVE; THERAPEUTIC EFFECTS; TUMORIGENESIS; WESTERN COUNTRIES;

ALGINATE; DRUG THERAPY;

DISEASES;

ALGINIC ACID; CHITOSAN; MICROSPHERE; OXALIPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG COATING; DRUG FORMULATION; DRUG RELEASE; IN VIVO STUDY; MALE; MICROENCAPSULATION; MOUSE; MUCOADHESION; NONHUMAN; PH; PRIORITY JOURNAL; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; DRUG COMPOUNDING; IMMUNOHISTOCHEMISTRY; LACTOFERRIN; MALE; MICE; MICE, INBRED C57BL; ORGANOPLATINUM COMPOUNDS;

EID: 84859870421     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.03.023     Document Type: Article

References (60)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al Cancer statistics, 2006 CA Cancer J Clin 2006, 56(2):106-130.
2. Wang D., Lippard S.J Cellular processing of platinum anticancer drugs Nat Rev Drug Discov 2005, 4(4):307-320.
3. Wang X., Guo Z Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents Dalton Trans 2008, 28(12):1521-1532.
4. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P A review on oxaliplatin-induced peripheral nerve damage Cancer Treat Rev 2008, 34(4):368-377.
5. Rabik C.A., Dolan M.E Molecular mechanisms of resistance and toxicity associated with platinating agents Cancer Treat Rev 2007, 33(1):9-23.
6. Pietrangeli A., Leandri M., Terzoli E., Jandolo B., Garufi C Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up Eur Neurol 2006, 56(1):13-16.
7. Michor F., Iwasa Y., Lengauer C., Nowak M.A Dynamics of colorectal cancer Semin Cancer Biol 2005, 15(6):484-493.
8. Nagda C.D., Chotai N.P., Nagda D.C., Patel S.B., Patel U.L Preparation and characterization of spray-dried mucoadhesive microspheres of ketorolac for nasal administration Curr Drug Deliv 2011, 21.
9. Choi J.S., Yoo H.S Pluronic/chitosan hydrogels containing epidermal growth factor with wound-adhesive and photo-crosslinkable properties J Biomed Mater Res A 2010, 95(2):564-573.
10. Jain A.K., Chalasani K.B., Khar R.K., Ahmed F.J., Diwan P.V Muco-adhesive multivesicular liposomes as an effective carrier for transmucosal insulin delivery J Drug Target 2007, 15(6):417-427.
11. Wu S.Y., Chang H.I., Burgess M., McMillan N.A Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system J Control Release 2011, 155(3):418-426.
12. Sahasathian T., Praphairaksit N., Muangsin N Mucoadhesive and floating chitosan-coated alginate beads for the controlled gastric release of amoxicillin Arch Pharm Res 2010, 33(6):889-899.
13. Cho W.J., Oh S.H., Lee J.H Alginate film as a novel post-surgical tissue adhesion barrier J Biomater Sci Polym Ed 2010, 21(6):701-713.
14. Penman A., Sanderson G.R A method for the determination of uronic acid sequence in alginates Carbohydr Res 1972, 25(2):273-282.
15. (FDA) UFaDA Food additive status list 2006.
16. Igoe R.S Dictionary of food ingredients 1983, Van Nostrand Reinhold Co, cop, New York 4th ed.
17. Wheatley M.A., Chang M., Park E., Langer R Coated alginate microspheres - factors influencing the controlled delivery of macromolecules J Appl Polym Sci 2003, 43(11):2123-2135.
18. Kim C.K., Lee E.J The controlled release of blue dextran from alginate beads Int J Pharm 1992, 79(1):11-19.
19. Singh O.N., Burgess J Characterization of albumin-alginic acid complex coacervation J Pharm Pharmacol 1989, 41(10):670-673.
20. Baldwin A.D., Kiick K.L Polysaccharide-modified synthetic polymeric biomaterials Biopolymers 2010, 94(1):128-140.
21. Tonnesen H.H., Karlsen J Alginate in drug delivery systems Drug Dev Ind Pharm 2002, 28(6):621-630.
22. Peters M.C., Isenberg B.C., Rowley J.A., Mooney D.J Release from alginate enhances the biological activity of vascular endothelial growth factor J Biomater Sci Polym Ed 1998, 9(12):1267-1278.
23. Sharma C.P., Paul W Chitosan, a drug carrier for the 21st century: a review Stp Pharma Sci 2000, 10(1):5-22.
24. Su L.K., Kinzler K.W., Vogelstein B., Preisinger A.C., Moser A.R., Luongo C., et al Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene Science 1992, 256(5057):668-670.
25. Love K.T., Mahon K.P., Levins C.G., Whitehead K.A., Querbes W., Dorkin J.R., et al Lipid-like materials for low-dose, in vivo gene silencing Proc Natl Acad Sci USA 2010, 107(5):1864-1869.
26. Huerta S., Irwin R.W., Heber D., Go V.L., Moatamed F., Ou C., et al Intestinal polyp formation in the Apcmin mouse: effects of levels of dietary calcium and altered vitamin D homeostasis Dig Dis Sci 2003, 48(5):870-876.
27. Terhaar Sive Droste J.S., Craanen M.E., van der Hulst R.W., Bartelsman J.F., Bezemer D.P., Cappendijk K.R., et al Colonoscopic yield of colorectal neoplasia in daily clinical practice World J Gastroenterol 2009, 15(9):1085-1092.
28. Rominiyi O., Broman D.M., Rajaganeshan R., Selvasekar C.R Colon cancer presenting with polymyositis-A case report Int J Surg Case Rep 2011, 2(7):225-227.
29. Sharma S., Longo W.E., Baniadam B., Vernava A.M Colorectal manifestations of endocrine disease Dis Colon Rectum 1995, 38(3):318-323.
30. Mecklenburg I., Leibig M., Weber C., Schmidbauer S., Folwaczny C Recurrent severe gastrointestinal bleeding and malabsorption due to extensive habitual megacolon World J Gastroenterol 2005, 11(48):7686-7687.
31. MacDermott R.P Alterations of the mucosal immune system in inflammatory bowel disease J Gastroenterol 1996, 31(6):907-916.
32. McClellan J.L., Davis J.M., Steiner J.L., Day S.D., Steck S.E., Carmichael M.D., et al Intestinal inflammatory cytokine response in relation to tumorigenesis in the Apc(Min/+) mouse Cytokine 2011, 57(11):113-119.
33. Playford R.J., Ghosh S Cytokines and growth factor modulators in intestinal inflammation and repair J Pathol 2005, 205(4):417-425.
34. Fuss I.J Cytokine network in inflammatory bowel disease Curr Drug Targets Inflamm Allergy 2003, 2(2):101-112.
35. Judd T.A., Day A.S., Lemberg D.A., Turner D., Leach S.T Update of fecal markers of inflammation in inflammatory bowel disease J Gastroenterol Hepatol 2011, 26(10):1493-1499.
36. Lee S., Choe J.W., Kim H.K., Sung J High-sensitivity C-reactive protein and cancer J Epidemiol 2011, 21(3):161-168.
37. Kim D.K., Oh S.Y., Kwon H.C., Lee S., Kwon K.A., Kim B.G., et al Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer BMC Cancer 2009, 9:155.
38. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 2002, 20(21):4285-4291.
39. Monk B.J., Sill M.W., McMeekin D.S., Cohn D.E., Ramondetta L.M., Boardman C.H., et al Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 2009, 27(28):4649-4655.
40. Zachos I., Konstantinopoulos P.A., Tzortzis V., Gravas S., Karatzas A., Karamouzis M.V., et al Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise Expert Opin Investig Drugs 2010, 19(7):875-887.
41. Moser A.R., Pitot H.C., Dove W.F A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse Science 1990, 247(4940):322-324.
42. Perkins S., Verschoyle R.D., Hill K., Parveen I., Threadgill M.D., Sharma R.A., et al Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis Cancer Epidemiol Biomarkers Prev 2002, 11(6):535-540.
43. Corpet D.E., Pierre F Point: from animal models to prevention of colon cancer Systematic review of chemoprevention in min mice and choice of the model system Cancer Epidemiol Biomarkers Prev 2003, 12(5):391-400.
44. Sethi G., Shanmugam M.K., Ramachandran L., Kumar A.P., Tergaonkar V Multifaceted link between cancer and inflammation Biosci Rep 2012, 32(1):1-15.
45. Lowe D.B., Storkus W.J Chronic inflammation and immunologic-based constraints in malignant disease Immunotherapy 2011, 3(10):1265-1274.
46. Hakansson A., Branning C., Molin G., Adawi D., Hagslatt M.L., Nyman M., et al Colorectal oncogenesis and inflammation in a rat model based on chronic inflammation due to cycling DSS treatments Gastroenterol Res Pract 2011, 924045.
47. Macarthur M., Hold G.L., El-Omar E.M Inflammation and cancer II Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy Am J Physiol Gastrointest Liver Physiol 2004, 286(4):G515-G520.
48. Langholz E., Munkholm P., Davidsen M., Binder V Course of ulcerative colitis: analysis of changes in disease activity over years Gastroenterology 1994, 107(1):3-11.
49. Kinoshita T., Ito H., Miki C Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma Cancer 1999, 85(12):2526-2531.
50. Tomita M., Wakabayashi H., Yamauchi K., Teraguchi S., Hayasawa H Bovine lactoferrin and lactoferricin derived from milk: production and applications Biochem Cell Biol 2002, 80(1):109-112.
51. Sugi K., Saitoh O., Hirata I., Katsu K Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins Am J Gastroenterol 1996, 91(5):927-934.
52. Kane S.V., Sandborn W.J., Rufo P.A., Zholudev A., Boone J., Lyerly D., et al Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation Am J Gastroenterol 2003, 98(6):1309-1314.
53. Baveye S., Elass E., Mazurier J., Spik G., Legrand D Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process Clin Chem Lab Med 1999, 37(3):281-286.
54. Shiu Y.C., Lin J.K., Huang C.J., Jiang J.K., Wang L.W., Huang H.C., et al Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum 2008, 51(4):443-449.
55. van de Poll M.C., Klaver Y.L., Lemmens V.E., Leenders B.J., Nienhuijs S.W., de Hingh I.H C-reactive protein concentration is associated with prognosis in patients suffering from peritoneal carcinomatosis of colorectal origin Int J Colorectal Dis 2011, 26(8):1067-1073.
56. Dymicka-Piekarska V., Matowicka-Karna J., Gryko M., Kemona-Chetnik I., Kemona H Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer Thromb Res 2007, 120(4):585-590.
57. Dockrell D.H Apoptotic cell death in the pathogenesis of infectious diseases J Infect 2001, 42(4):227-234.
58. Oshima M., Taketo M.M COX selectivity and animal models for colon cancer Curr Pharm Des 2002, 8(12):1021-1034.
59. Arai M., Sasaki A., Saito N., Nakazato Y Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system Pathol Int 2005, 55(3):122-129.
60. Gerdes J., Dallenbach F., Lennert K., Lemke H., Stein H Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67 Hematol Oncol 1984, 2(4):365-371.